Clinical trials: Thoracic Neoplasm
Lung Cancer, Non Small Cell Lung Cancer
Perioperative Rehabilitation in Operation for Lung Cancer
Background: Improved surgical techniques combined with effective adjuvant chemotherapy, has led to a better survival in individuals with NSCLC.
- Trial name
- PROLUCA (NCT01893580)
- Testing
- Experimental: 1. Experimental, Experimental: 2. Experimental, Experimental: 3. Experimental
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Lung Cancer
Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90-DOTA-tyr3-octreotide can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006370
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween: ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada)…
- Trial name
- NCT04145570
- Testing
- Erlotinib HCl 150 mg, Tarceva®
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Quadras Scientific Solutions
Lung Cancer
Lung Cancer Vaccine Plus Oral Dietary Supplement
This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance immune recognition of tumor cells in patients with lung cancer.
- Trial name
- NCT01829373
- Testing
- vaccine 1650-G
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Edward Hirschowitz
Small Cell Lung Cancer
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
This Phase II study was designed to evaluate the safety and efficacy of albumin paclitaxel in combination with simvastatin compared with treatment with albumin paclitaxel alone in ES-SCLC patients relapsed from first-line…
- Trial name
- NCT04698941
- Testing
- Albumin Paclitaxel, Simvastatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer, Stage IIIA-cN2
Molecular Signature From Tumor to Lymph Nodes
Mediastinal lymph node (LN) involvement (N2) in non-small cell lung cancer (NSCLC) concerns 15% of resectable tumors and is associated with a poor prognosis and an overall survival reaching 9 to 49%.
- Conditions
- Lung Cancer, Stage IIIA-cN2, Operated With Curative Intent, Primary Tumor Tissue Available
- Trial name
- N2-3S (NCT04677205)
- Where
- 12 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Cancer (NSCLC)
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT00821951
- Testing
- Vorinostat, Radiotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Non-small Cell Lung Cancer
Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
To better understand your feelings and expectations about immunotherapy
- Trial name
- NCT05634551
- Testing
- Questionnaires, Interview
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Small-cell Lung Cancer
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
- Trial name
- NCT04342429
- Testing
- Proton-beam Therapy for Small Cell Lung Cancer
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07017829
- Testing
- Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression.
- Trial name
- NCT02659631
- Testing
- PF-06671008
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Non-small-cell Lung Cancer
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Planned study population consists of approximately 1500 adult patients with a/m NSCLC in Russia, in about 20 oncological centers (in each center it is expected to recruit about 75 patients) in different regions of Russia in order…
- Trial name
- NCT06245837
- Where
- 16 sites in Russia
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Lung Cancer
Respiration Gated Laser Guided CT Lung Nodule Biopsy
The primary outcome of this study is to investigate the accuracy of respiration gated laser guided CT lung nodule biopsy through a prospective randomized trial using a bellows-based breath hold monitoring system.
- Trial name
- GENCTBIOPSY (NCT01236937)
- Testing
- Bellows-based breath hold device
- Where
- Denmark
- Volunteers
- 400 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Lung Cancer
The Use of a Quality of Life Questionnaire in Patients With Lung Cancer
This study will investigate the effectiveness of using the European Organisation for Research and Treatment of cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC 13) to identify and target therapies in patients with…
- Trial name
- NCT01213745
- Testing
- Intervention, Attention, Control
- Where
- United Kingdom
- Volunteers
- 138 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-small Cell Lung Cancer
Impact of Lazertinib Dose Modification on Effectiveness and Safety
The primary objective is to evaluate Progression Free Survival (PFS) of the group (160 mg group) in which dose reduction was performed for 12 weeks after the first administration of Lazertinib.
- Trial name
- NCT05716672
- Testing
- Lazertinib
- Where
- 11 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Pusan National University Hospital
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population, with 5-year survival rates ranging from 10% to 30%.
- Trial name
- NCT02977169
- Testing
- PORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Prolonged Air Leak, Persistent Air Leak
Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for Postoperative Air Leak After Lung Resections
Prolonged or persistent air leak (PAL) is one of the most common complications in patients after surgery on the lung parenchyma.
- Trial name
- GLUC-PAL (NCT06936969)
- Testing
- Autologous blood patch pleurodesis, 40% glucose solution pleurodesis
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii
Lung Cancer
The Role of Interventional Pulmonology, Microbiota and Immune Response in the Patient With Lung Cancer
This study is designed to evaluate complications, specificity, diagnostic yield of radial endobronchial ultrasound guided transbronchial cryobiopsy and transbronchial forceps biopsy with fluoroscopy in the diagnosis of peripheral…
- Trial name
- RIPMIRLC (NCT05164445)
- Testing
- Transbronchial forceps biopsy, Transbronchial forceps biopsy+Transbronchial cryobiopsy
- Where
- Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences